Back to search
FDAFDA · Food and drugs·Recall number D-921-2013

Bethel 30 capsules, packaged in 30 count bottles, Distributed by BETHEL INC. New York, New York

Published September 4, 2013 · Recall initiated: June 11, 2013

Summary

FDA records drug Class I recall D-921-2013, published September 4, 2013 and initiated June 11, 2013. Recalling firm: Bethel Nutritional Consulting, Inc; Status: Terminated; Reported quantity: 18,678 bottles; Lot: Lot #: 120514, EXP: 12/2014. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without An Approved NDA/ANDA: FDA analysis found this product contained undeclared sibutramine and phenolphthalein, two active ingredients that were once marketed in the U.S. but removed due to safety reasons, making this product an unapproved new drug.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Bethel Nutritional Consulting, Inc
Distributor
Nationwide. Product was also available for sale via internet
Lot
Lot #: 120514, EXP: 12/2014
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Bethel 30 capsules, packaged in 30 count bottles, Distributed by BETHEL INC. New York, New York recalled?

Yes. FDA published recall D-921-2013 on September 4, 2013. Reported hazard: Marketed Without An Approved NDA/ANDA: FDA analysis found this product contained undeclared sibutramine and phenolphthalein, two active ingredients that were once marketed in the U.S. but removed due to safety reasons, making this product an unapproved new drug.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit